The Risks of Perioperative Hypotension
For millions of adults over the age of 60, daily blood pressure management is a standard part of cardiovascular health. However, these same life-saving medications—specifically ACE inhibitors and angiotensin receptor blockers (ARBs)—can present a hidden danger when those patients undergo surgery. Anesthesiologists have long debated the necessity of taking these medications on the morning of an operation, as maintaining anesthesia often conflicts with the drugs' physiological effects, potentially leading to intraoperative hypotension (critically low blood pressure).
When a patient experiences severe drops in blood pressure during an operation, the consequences can be dire. Clinical data has previously linked such events to heightened risks of acute kidney injury, cardiac complications, and, in severe instances, mortality. Despite the known risks, clinical guidelines regarding pre-surgical medication management have remained ambiguous, often providing only weak recommendations that leave clinicians to rely on intuition rather than high-certainty empirical evidence.
The Clinical Trial Breakdown
To resolve this medical uncertainty, researchers conducted a rigorous, multi-center, randomized, double-blind trial involving 2,012 patients aged 60 to 80. These participants, all of whom had been on long-term antihypertensive therapy for an average of a decade, were scheduled for noncardiac procedures under general anesthesia. By splitting the cohort into two groups—one continuing their morning medication and the other receiving an identical placebo—the research team was able to isolate the direct impact of the medication on surgical outcomes.
The results provided clear, actionable data. Patients who omitted their medication on the morning of their surgery demonstrated a significantly lower rate of intraoperative hypotension. Specifically, 31.2% of the placebo group experienced low blood pressure events, compared to a staggering 45.5% in the group that continued their medication. Furthermore, the duration of these hypotension episodes was shortened, and the necessity for vasopressor intervention—drugs used to artificially boost blood pressure during critical moments—dropped from 41.1% in the control group to just 28.5% in those who skipped their dose.
Context and Future Implications
The findings, recently published in The BMJ, represent a major shift in perioperative care strategies. By proving that the cessation of these specific drug classes is both safe and effective at mitigating intraoperative risk, the study provides a robust foundation for updating international medical guidelines.
- Study Population: 2,012 patients, aged 60-80, undergoing noncardiac surgery.
- Medication Focus: ACE inhibitors and ARBs, typically taken for over 10 years.
- Primary Benefit: Nearly a 14% absolute reduction in intraoperative hypotension events.
- Outcome: Decreased reliance on reactive vasopressor drugs and shorter duration of instability.
While the study highlights substantial benefits regarding blood pressure stability, it also noted that there were no statistically significant differences in 30-day post-operative complications or mortality rates between the two groups. As the researchers continue to analyze long-term health metrics, the current recommendation suggests that for most older adults undergoing elective noncardiac procedures, pausing ACE inhibitors and ARBs on the day of surgery is a simple, high-certainty intervention that should become the new standard of care.
